Dabur Says USFDA Observations Will Not Hit Finances Or Operations

Clarification On USFDA Observations

In its statement, Dabur emphasised that the USFDA’s findings are being addressed through a structured remediation roadmap, in line with global quality and compliance standards. The company underlined that the observations do not disrupt production at the Silvassa site, nor do they impair its ability to service domestic or export markets.

Engagement And Compliance Roadmap

Dabur noted that it is actively engaged with the USFDA on the inspection findings, responding point-by-point and implementing corrective measures where required. Management reiterated its commitment to stringent quality systems, continuous monitoring and timely compliance, aiming to close out the regulatory queries without any material adverse consequences.

Reassurance For Investors And Stakeholders

By stating explicitly that there is no impact on financials or operational activities, Dabur is seeking to reassure shareholders, creditors and business partners. The company’s communication suggests that the observations are manageable within normal course compliance and do not warrant any revision to its current business outlook or guidance.

Key Highlights

1. Dabur says USFDA observations have no impact on financial or operational activities
2. Silvassa plant remains fully operational despite inspection findings
3. Corrective and preventive action plan already shared with USFDA
4. Company actively engaged with regulator to address all observations
5. Management reiterates commitment to global-quality and compliance standards

Sources: Company statements and regulatory communication regarding USFDA observations at the Silvassa facility